Posted by Michael Wonder on 26 Jul 2024
US FDA approves BioMarin's Brineura (cerliponase alfa) for children under 3 years with CLN2 disease
24 July 2024 - Now approved for children of all ages with CLN2 Batten disease, regardless of whether they yet show symptoms.
BioMarin Pharmaceutical today announced that the US FDA has approved the company's supplemental biologics license application for Brineura (cerliponase alfa) to slow the loss of ambulation in children of all ages with neuronal ceroid lipofuscinosis type 2, also known as tripeptidyl peptidase 1 deficiency.
